Wednesday, April 8, 2026

STAAR Surgical prelim Q1 2026 net sales > $90 m, more than doubling prior-year quarter

 


  • Growth in preliminary Q1 2026 net sales was driven primarily by China.
  • Company expects the strong Q1 2026 sales performance to deliver a meaningful improvement in adjusted EBITDA.
at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.